Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SGUGL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Ispectamab debotansine
|
|||||
| Synonyms |
ispectamab debotansine; CC-99712
Click to Show/Hide
|
|||||
| Organization |
Sutro Biopharma (Originator) (No Rights);Celgene (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Ispectamab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
SC347
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Cys-12 ADC linker
|
Linker Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
| Combination Type |
debotansine
|
|||||
| Special Approval(s) |
Orphan drug (FDA)
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants must be ≥18 with measurable relapsed/refractory MM and ECOG 0-1, excluding those with CNS involvement, recent transplants (auto≤3mo/allo≤6mo), active HBV/HCV/HIV, pregnancy/lactation, or GVHD immunosuppression, with additional protocol-specified criteria applying.
|
||||
| Administration Dosage |
CC-99712 will be administered via intravenous (IV) infusion.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04036461 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | ||||
| Primary Endpoint |
The trial evaluates safety through adverse event monitoring (42+ days post-treatment), determines Maximum Tolerated Dose (≤33% DLT rate in first cycle), and assesses Dose Limiting Toxicities within 28 days in relapsed/refractory multiple myeloma patients.
|
||||
| Other Endpoint |
Key efficacy endpoints include IMWG-defined Overall Response Rate, Time to Response, Duration of Response, Progression-Free Survival, and Overall Survival (all tracked up to 3 years). Pharmacokinetic parameters (Cmax, Tmax, AUC, CLT, Ctrough) and anti-drug antibody development are also evaluated throughout the 3-year study period.
|
||||
References